Published in Lab Business Week, September 13th, 2009
"The United States Patent Office's issuance of this patent provides BDSI longer and more extensive protection for both ONSOLIS and the BEMA platform technology," stated Charles Dadswell, General Counsel for BDSI. "The U.S. Patent Office has acknowledged and extended the expiration date of the patent by 835 days. However, BDSI believes it is entitled to, and will request, a further extension of this period that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.